Brain Injury and Ketamine: a prospective, randomized controlled double blind clinical trial to study the effects of ketamine on therapy intensity level and intracranial pressure in acute brain injury patients.
- Conditions
- Traumatic brain injuryMedDRA version: 26.1Level: LLTClassification code: 10060690Term: Traumatic brain injury Class: 10022117Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03]
- Registration Number
- CTIS2023-505319-19-00
- Lead Sponsor
- Z Leuven
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 100
Traumatic brain injury patients, Age = 18 years, Admitted to the Intensive Care Unit, Within 72 hours after admission to the initial hospital: ICP monitor in place (parenchymal probe, ventricular catheter, or both) and requiring sedation
Known pregnancy and/or lactation, Imminent or actual brain death upon inclusion, Allergy or intolerance to the study medication, Pre-existing neurocognitive disorders, pre-existing congenital or non-congenital brain dysfunction., Inability to obtain informed consent, Inclusion in an IMP-RCT of which the PI indicates that co-inclusion specifically in the BIKe study is prohibited, Therapy restriction code upon inclusion, Porphyria, Glaucoma
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: To demonstrate that associating ketamine to the sedative regime for ICP control in TBI, results in a reduction of the therapeutic intensity of ICP reducing measures, assessed by the TIL score.;Secondary Objective: To demonstrate that ketamine does not cause an increase in ICP.;Primary end point(s): Reduction in cumulative daily TIL score., The number of high intracranial pressure episodes defined as an ICP >22 mmHg for >25 minutes
- Secondary Outcome Measures
Name Time Method